论文部分内容阅读
埃博拉病毒(EBOV)在其感染的人群中引起高达90%的致死性疾病。疫苗中,只有疱疹性口炎病毒平台已经成功地在非人灵长类动物中提供了暴露后的保护。在这里,作者表明,人类腺病毒5型(Ad5)作为载体的佐剂疫苗(Ad5-扎伊尔埃博拉病毒糖蛋白)在埃博拉病毒攻击后30 min和24 h进
Ebola virus (EBOV) causes up to 90% of fatal diseases in its infected population. Of the vaccines, only the vesicular stomatitis virus platform has successfully provided post-exposure protection in non-human primates. Here, the authors show that the adjuvanted vaccine (Ad5-Zaire Ebola virus glycoprotein) of human adenovirus type 5 (Ad5) as a carrier progresses at 30 min and 24 h after Ebola virus challenge